2021
10:00 AM - 11:00 AM
Thursday Thu
Register for Zoom Details
Research Seminar Series: Michael Snyder
Cutting Edge Research and Biobanking with the Lakota
The rich diversity of American Indian peoples in the US are severely under-represented despite the rapid expansion of biological sample collection and precision health sciences. To better address this, and respect and harmonize cultural, data sovereignty and scientific practices, we have worked alongside a Northern Plains Tribe on the first Indigenous led Bio-Data Repository fully within tribal jurisdiction.
The Native BioData Consortium on the Cheyenne River Sioux reservation was created in September 2018 and is paralleled with our ongoing work centered around American Indian autoimmune disease (SAIL-Studies in Auto-immune Illnesses with the Lakota). Samples and data for this work are a proof of concept taking into light the scientific, social, legal and cultural issues involving Tribal data. This enterprise will be a powerful “irrigation” engine for co-education and helping tribal nations build capacity in business, infrastructure and personnel.
Additionally, the biobank/lab will also be a resource for the Tribe, particularly with our current efforts to better support COVID-19 monitoring in a Tribal setting with advances in swab/serology testing and wearables.
Speaker
Michael Snyder, Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine
Stanford University School of Medicine Department of Genetics
Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and multiomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor (TF) binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated (e.g. lncRNAs and TF binding sites), and a high diversity of transcription factor binding occurs both between and within species.
He launched the field of personalized medicine by combining different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person, and his laboratory pioneered the use of wearables technologies (smart watches and continuous glucose monitoring) for precision health.
He is a cofounder of many biotechnology companies, including Personalis, SensOmics, Qbio, January, Protos, Oralome, Mirvie and Filtricine.